Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans
Sedentary obesity is associated with increased risk of many cardio-metabolic diseases, including type 2 diabetes. Weight loss is therefore a desirable goal for sedentary adults with obesity. Weight loss is also a well-documented side effect of sodium glucose co-transporter 2 (SGLT2) inhibition, a ph...
Gespeichert in:
| Veröffentlicht in: | Nutrients 2020-02, Vol.12 (2), p.510 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 510 |
| container_title | Nutrients |
| container_volume | 12 |
| creator | Ryan, Shane P P Newman, Alissa A Wilburn, Jessie R Rhoades, Lauren D Trikha, S Raj J Godwin, Ellen C Schoenberg, Hayden M Battson, Micah L Ewell, Taylor R Luckasen, Gary J Biela, Laurie M Melby, Christopher L Bell, Christopher |
| description | Sedentary obesity is associated with increased risk of many cardio-metabolic diseases, including type 2 diabetes. Weight loss is therefore a desirable goal for sedentary adults with obesity. Weight loss is also a well-documented side effect of sodium glucose co-transporter 2 (SGLT2) inhibition, a pharmaceutical strategy for diabetes treatment. We hypothesized that, compared with placebo, SGLT2 inhibition as an adjunct to out-patient dietary counselling for weight loss would lead to more favorable modification of body mass and composition, and greater improvement in glucose regulation and lipid profile. Using a randomized, double-blind, repeated measures parallel design, 50 sedentary men and women (body mass index: 33.4 ± 4.7 kg/m
; mean ± SD) were assigned to 12 weeks of dietary counselling, supplemented with daily ingestion of either a placebo or SGLT2 inhibitor (dapagliflozin: up to 10 mg/day). Dietary counselling favorably modified body mass, body fat, glucose regulation, and fasting concentrations of triglyceride and very low-density lipoprotein cholesterol (main effects of counselling:
< 0.05); SGLT2 inhibition did not influence any of these adaptations (counselling × medication interactions:
> 0.05). However, SGLT2 inhibition when combined with dietary counselling led to greater loss of fat-free mass (counselling × medication interaction:
= 0.047) and attenuated the rise in high-density lipoprotein cholesterol (counselling × medication interaction:
= 0.028). In light of these data and the health implications of decreased fat-free mass, we recommend careful consideration before implementing SGLT2 inhibition as an adjunct to dietary counselling for weight loss in sedentary adults with obesity. |
| doi_str_mv | 10.3390/nu12020510 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7071188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2362074086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-b2954d6920cbc860ef764467c1c684f446b26601a7dd90d99590a49ef71009f03</originalsourceid><addsrcrecordid>eNpdksFu1DAQhiMEolXphQdAlrggRGDiJE58Qaq2bFupsIiWc-Q4k42rxN7azqJ9MN6PWVpKwRePxt_8-j0zSfIyg_d5LuGDnTMOHMoMniSHHCqeClHkTx_FB8lxCDewPxVUIn-eHOQc6jKXxWHy88p1Zp7Y2ThrF5AtXHrtlQ0b5yN6xtmFHUxronGWnToM7IuLbKm2zqt23LHPVN3vWByQfR12wbjRrY1WI_uGJGEDFUTHTg1G5XckPlNqHI1dM0N6RrUYMaRLj_iOXWGH9je32qL_gWY9RKZsx1YtkrOTbh4jO58ncvciedarMeDx_X2UfF9-ul6cp5ers4vFyWWqCxAxbbksi05IDrrVtQDsK1EUotKZFnXRU9hyISBTVddJ6KQsJahCEpYByB7yo-Tjne5mbifsNPnzamw23kzks3HKNP--WDM0a7dtqNFZVtck8OZewLvbGUNsJhM0tUBZdHNoeC5oTgXUgtDX_6E3bvaWvkeULIHXZbV39PaO0t6F4LF_MJNBs1-I5u9CEPzqsf0H9M_4819TCLK4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2395028570</pqid></control><display><type>article</type><title>Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Ryan, Shane P P ; Newman, Alissa A ; Wilburn, Jessie R ; Rhoades, Lauren D ; Trikha, S Raj J ; Godwin, Ellen C ; Schoenberg, Hayden M ; Battson, Micah L ; Ewell, Taylor R ; Luckasen, Gary J ; Biela, Laurie M ; Melby, Christopher L ; Bell, Christopher</creator><creatorcontrib>Ryan, Shane P P ; Newman, Alissa A ; Wilburn, Jessie R ; Rhoades, Lauren D ; Trikha, S Raj J ; Godwin, Ellen C ; Schoenberg, Hayden M ; Battson, Micah L ; Ewell, Taylor R ; Luckasen, Gary J ; Biela, Laurie M ; Melby, Christopher L ; Bell, Christopher</creatorcontrib><description>Sedentary obesity is associated with increased risk of many cardio-metabolic diseases, including type 2 diabetes. Weight loss is therefore a desirable goal for sedentary adults with obesity. Weight loss is also a well-documented side effect of sodium glucose co-transporter 2 (SGLT2) inhibition, a pharmaceutical strategy for diabetes treatment. We hypothesized that, compared with placebo, SGLT2 inhibition as an adjunct to out-patient dietary counselling for weight loss would lead to more favorable modification of body mass and composition, and greater improvement in glucose regulation and lipid profile. Using a randomized, double-blind, repeated measures parallel design, 50 sedentary men and women (body mass index: 33.4 ± 4.7 kg/m
; mean ± SD) were assigned to 12 weeks of dietary counselling, supplemented with daily ingestion of either a placebo or SGLT2 inhibitor (dapagliflozin: up to 10 mg/day). Dietary counselling favorably modified body mass, body fat, glucose regulation, and fasting concentrations of triglyceride and very low-density lipoprotein cholesterol (main effects of counselling:
< 0.05); SGLT2 inhibition did not influence any of these adaptations (counselling × medication interactions:
> 0.05). However, SGLT2 inhibition when combined with dietary counselling led to greater loss of fat-free mass (counselling × medication interaction:
= 0.047) and attenuated the rise in high-density lipoprotein cholesterol (counselling × medication interaction:
= 0.028). In light of these data and the health implications of decreased fat-free mass, we recommend careful consideration before implementing SGLT2 inhibition as an adjunct to dietary counselling for weight loss in sedentary adults with obesity.</description><identifier>ISSN: 2072-6643</identifier><identifier>EISSN: 2072-6643</identifier><identifier>DOI: 10.3390/nu12020510</identifier><identifier>PMID: 32085394</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adaptation ; Adolescent ; Adult ; Adults ; Aged ; Appetite ; Automation ; Benzhydryl Compounds - administration & dosage ; Body composition ; Body fat ; Body Fat Distribution ; Body mass ; Body Mass Index ; Body size ; Body weight ; Body weight loss ; Caffeine ; Carbohydrates ; Cholesterol ; Counseling ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diet, Reducing ; Directive Counseling ; Double-Blind Method ; Exercise ; Fat-free body mass ; Female ; Food ; Glucose ; Glucose - metabolism ; Glucose transporter ; Glucosides - administration & dosage ; Health risks ; Humans ; Hunger ; Ingestion ; Inhibition ; Insulin ; Laboratories ; Lipids ; Lipoproteins, VLDL - metabolism ; Male ; Metabolic disorders ; Middle Aged ; Obesity ; Obesity - metabolism ; Obesity - therapy ; Overweight - metabolism ; Overweight - therapy ; Physical fitness ; Physiological responses ; Sedentary behavior ; Short term ; Side effects ; Sodium ; Sodium-Glucose Transporter 2 Inhibitors - administration & dosage ; Treatment Outcome ; Triglycerides ; Triglycerides - metabolism ; Weight control ; Weight loss ; Weight Reduction Programs ; Young Adult</subject><ispartof>Nutrients, 2020-02, Vol.12 (2), p.510</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-b2954d6920cbc860ef764467c1c684f446b26601a7dd90d99590a49ef71009f03</citedby><cites>FETCH-LOGICAL-c406t-b2954d6920cbc860ef764467c1c684f446b26601a7dd90d99590a49ef71009f03</cites><orcidid>0000-0003-2478-1844 ; 0000-0001-8220-9745 ; 0000-0002-7706-0912</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071188/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071188/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32085394$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ryan, Shane P P</creatorcontrib><creatorcontrib>Newman, Alissa A</creatorcontrib><creatorcontrib>Wilburn, Jessie R</creatorcontrib><creatorcontrib>Rhoades, Lauren D</creatorcontrib><creatorcontrib>Trikha, S Raj J</creatorcontrib><creatorcontrib>Godwin, Ellen C</creatorcontrib><creatorcontrib>Schoenberg, Hayden M</creatorcontrib><creatorcontrib>Battson, Micah L</creatorcontrib><creatorcontrib>Ewell, Taylor R</creatorcontrib><creatorcontrib>Luckasen, Gary J</creatorcontrib><creatorcontrib>Biela, Laurie M</creatorcontrib><creatorcontrib>Melby, Christopher L</creatorcontrib><creatorcontrib>Bell, Christopher</creatorcontrib><title>Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans</title><title>Nutrients</title><addtitle>Nutrients</addtitle><description>Sedentary obesity is associated with increased risk of many cardio-metabolic diseases, including type 2 diabetes. Weight loss is therefore a desirable goal for sedentary adults with obesity. Weight loss is also a well-documented side effect of sodium glucose co-transporter 2 (SGLT2) inhibition, a pharmaceutical strategy for diabetes treatment. We hypothesized that, compared with placebo, SGLT2 inhibition as an adjunct to out-patient dietary counselling for weight loss would lead to more favorable modification of body mass and composition, and greater improvement in glucose regulation and lipid profile. Using a randomized, double-blind, repeated measures parallel design, 50 sedentary men and women (body mass index: 33.4 ± 4.7 kg/m
; mean ± SD) were assigned to 12 weeks of dietary counselling, supplemented with daily ingestion of either a placebo or SGLT2 inhibitor (dapagliflozin: up to 10 mg/day). Dietary counselling favorably modified body mass, body fat, glucose regulation, and fasting concentrations of triglyceride and very low-density lipoprotein cholesterol (main effects of counselling:
< 0.05); SGLT2 inhibition did not influence any of these adaptations (counselling × medication interactions:
> 0.05). However, SGLT2 inhibition when combined with dietary counselling led to greater loss of fat-free mass (counselling × medication interaction:
= 0.047) and attenuated the rise in high-density lipoprotein cholesterol (counselling × medication interaction:
= 0.028). In light of these data and the health implications of decreased fat-free mass, we recommend careful consideration before implementing SGLT2 inhibition as an adjunct to dietary counselling for weight loss in sedentary adults with obesity.</description><subject>Adaptation</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Adults</subject><subject>Aged</subject><subject>Appetite</subject><subject>Automation</subject><subject>Benzhydryl Compounds - administration & dosage</subject><subject>Body composition</subject><subject>Body fat</subject><subject>Body Fat Distribution</subject><subject>Body mass</subject><subject>Body Mass Index</subject><subject>Body size</subject><subject>Body weight</subject><subject>Body weight loss</subject><subject>Caffeine</subject><subject>Carbohydrates</subject><subject>Cholesterol</subject><subject>Counseling</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diet, Reducing</subject><subject>Directive Counseling</subject><subject>Double-Blind Method</subject><subject>Exercise</subject><subject>Fat-free body mass</subject><subject>Female</subject><subject>Food</subject><subject>Glucose</subject><subject>Glucose - metabolism</subject><subject>Glucose transporter</subject><subject>Glucosides - administration & dosage</subject><subject>Health risks</subject><subject>Humans</subject><subject>Hunger</subject><subject>Ingestion</subject><subject>Inhibition</subject><subject>Insulin</subject><subject>Laboratories</subject><subject>Lipids</subject><subject>Lipoproteins, VLDL - metabolism</subject><subject>Male</subject><subject>Metabolic disorders</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Obesity - metabolism</subject><subject>Obesity - therapy</subject><subject>Overweight - metabolism</subject><subject>Overweight - therapy</subject><subject>Physical fitness</subject><subject>Physiological responses</subject><subject>Sedentary behavior</subject><subject>Short term</subject><subject>Side effects</subject><subject>Sodium</subject><subject>Sodium-Glucose Transporter 2 Inhibitors - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Triglycerides</subject><subject>Triglycerides - metabolism</subject><subject>Weight control</subject><subject>Weight loss</subject><subject>Weight Reduction Programs</subject><subject>Young Adult</subject><issn>2072-6643</issn><issn>2072-6643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdksFu1DAQhiMEolXphQdAlrggRGDiJE58Qaq2bFupsIiWc-Q4k42rxN7azqJ9MN6PWVpKwRePxt_8-j0zSfIyg_d5LuGDnTMOHMoMniSHHCqeClHkTx_FB8lxCDewPxVUIn-eHOQc6jKXxWHy88p1Zp7Y2ThrF5AtXHrtlQ0b5yN6xtmFHUxronGWnToM7IuLbKm2zqt23LHPVN3vWByQfR12wbjRrY1WI_uGJGEDFUTHTg1G5XckPlNqHI1dM0N6RrUYMaRLj_iOXWGH9je32qL_gWY9RKZsx1YtkrOTbh4jO58ncvciedarMeDx_X2UfF9-ul6cp5ers4vFyWWqCxAxbbksi05IDrrVtQDsK1EUotKZFnXRU9hyISBTVddJ6KQsJahCEpYByB7yo-Tjne5mbifsNPnzamw23kzks3HKNP--WDM0a7dtqNFZVtck8OZewLvbGUNsJhM0tUBZdHNoeC5oTgXUgtDX_6E3bvaWvkeULIHXZbV39PaO0t6F4LF_MJNBs1-I5u9CEPzqsf0H9M_4819TCLK4</recordid><startdate>20200218</startdate><enddate>20200218</enddate><creator>Ryan, Shane P P</creator><creator>Newman, Alissa A</creator><creator>Wilburn, Jessie R</creator><creator>Rhoades, Lauren D</creator><creator>Trikha, S Raj J</creator><creator>Godwin, Ellen C</creator><creator>Schoenberg, Hayden M</creator><creator>Battson, Micah L</creator><creator>Ewell, Taylor R</creator><creator>Luckasen, Gary J</creator><creator>Biela, Laurie M</creator><creator>Melby, Christopher L</creator><creator>Bell, Christopher</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2478-1844</orcidid><orcidid>https://orcid.org/0000-0001-8220-9745</orcidid><orcidid>https://orcid.org/0000-0002-7706-0912</orcidid></search><sort><creationdate>20200218</creationdate><title>Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans</title><author>Ryan, Shane P P ; Newman, Alissa A ; Wilburn, Jessie R ; Rhoades, Lauren D ; Trikha, S Raj J ; Godwin, Ellen C ; Schoenberg, Hayden M ; Battson, Micah L ; Ewell, Taylor R ; Luckasen, Gary J ; Biela, Laurie M ; Melby, Christopher L ; Bell, Christopher</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-b2954d6920cbc860ef764467c1c684f446b26601a7dd90d99590a49ef71009f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adaptation</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Adults</topic><topic>Aged</topic><topic>Appetite</topic><topic>Automation</topic><topic>Benzhydryl Compounds - administration & dosage</topic><topic>Body composition</topic><topic>Body fat</topic><topic>Body Fat Distribution</topic><topic>Body mass</topic><topic>Body Mass Index</topic><topic>Body size</topic><topic>Body weight</topic><topic>Body weight loss</topic><topic>Caffeine</topic><topic>Carbohydrates</topic><topic>Cholesterol</topic><topic>Counseling</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diet, Reducing</topic><topic>Directive Counseling</topic><topic>Double-Blind Method</topic><topic>Exercise</topic><topic>Fat-free body mass</topic><topic>Female</topic><topic>Food</topic><topic>Glucose</topic><topic>Glucose - metabolism</topic><topic>Glucose transporter</topic><topic>Glucosides - administration & dosage</topic><topic>Health risks</topic><topic>Humans</topic><topic>Hunger</topic><topic>Ingestion</topic><topic>Inhibition</topic><topic>Insulin</topic><topic>Laboratories</topic><topic>Lipids</topic><topic>Lipoproteins, VLDL - metabolism</topic><topic>Male</topic><topic>Metabolic disorders</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Obesity - metabolism</topic><topic>Obesity - therapy</topic><topic>Overweight - metabolism</topic><topic>Overweight - therapy</topic><topic>Physical fitness</topic><topic>Physiological responses</topic><topic>Sedentary behavior</topic><topic>Short term</topic><topic>Side effects</topic><topic>Sodium</topic><topic>Sodium-Glucose Transporter 2 Inhibitors - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Triglycerides</topic><topic>Triglycerides - metabolism</topic><topic>Weight control</topic><topic>Weight loss</topic><topic>Weight Reduction Programs</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ryan, Shane P P</creatorcontrib><creatorcontrib>Newman, Alissa A</creatorcontrib><creatorcontrib>Wilburn, Jessie R</creatorcontrib><creatorcontrib>Rhoades, Lauren D</creatorcontrib><creatorcontrib>Trikha, S Raj J</creatorcontrib><creatorcontrib>Godwin, Ellen C</creatorcontrib><creatorcontrib>Schoenberg, Hayden M</creatorcontrib><creatorcontrib>Battson, Micah L</creatorcontrib><creatorcontrib>Ewell, Taylor R</creatorcontrib><creatorcontrib>Luckasen, Gary J</creatorcontrib><creatorcontrib>Biela, Laurie M</creatorcontrib><creatorcontrib>Melby, Christopher L</creatorcontrib><creatorcontrib>Bell, Christopher</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nutrients</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ryan, Shane P P</au><au>Newman, Alissa A</au><au>Wilburn, Jessie R</au><au>Rhoades, Lauren D</au><au>Trikha, S Raj J</au><au>Godwin, Ellen C</au><au>Schoenberg, Hayden M</au><au>Battson, Micah L</au><au>Ewell, Taylor R</au><au>Luckasen, Gary J</au><au>Biela, Laurie M</au><au>Melby, Christopher L</au><au>Bell, Christopher</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans</atitle><jtitle>Nutrients</jtitle><addtitle>Nutrients</addtitle><date>2020-02-18</date><risdate>2020</risdate><volume>12</volume><issue>2</issue><spage>510</spage><pages>510-</pages><issn>2072-6643</issn><eissn>2072-6643</eissn><abstract>Sedentary obesity is associated with increased risk of many cardio-metabolic diseases, including type 2 diabetes. Weight loss is therefore a desirable goal for sedentary adults with obesity. Weight loss is also a well-documented side effect of sodium glucose co-transporter 2 (SGLT2) inhibition, a pharmaceutical strategy for diabetes treatment. We hypothesized that, compared with placebo, SGLT2 inhibition as an adjunct to out-patient dietary counselling for weight loss would lead to more favorable modification of body mass and composition, and greater improvement in glucose regulation and lipid profile. Using a randomized, double-blind, repeated measures parallel design, 50 sedentary men and women (body mass index: 33.4 ± 4.7 kg/m
; mean ± SD) were assigned to 12 weeks of dietary counselling, supplemented with daily ingestion of either a placebo or SGLT2 inhibitor (dapagliflozin: up to 10 mg/day). Dietary counselling favorably modified body mass, body fat, glucose regulation, and fasting concentrations of triglyceride and very low-density lipoprotein cholesterol (main effects of counselling:
< 0.05); SGLT2 inhibition did not influence any of these adaptations (counselling × medication interactions:
> 0.05). However, SGLT2 inhibition when combined with dietary counselling led to greater loss of fat-free mass (counselling × medication interaction:
= 0.047) and attenuated the rise in high-density lipoprotein cholesterol (counselling × medication interaction:
= 0.028). In light of these data and the health implications of decreased fat-free mass, we recommend careful consideration before implementing SGLT2 inhibition as an adjunct to dietary counselling for weight loss in sedentary adults with obesity.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>32085394</pmid><doi>10.3390/nu12020510</doi><orcidid>https://orcid.org/0000-0003-2478-1844</orcidid><orcidid>https://orcid.org/0000-0001-8220-9745</orcidid><orcidid>https://orcid.org/0000-0002-7706-0912</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6643 |
| ispartof | Nutrients, 2020-02, Vol.12 (2), p.510 |
| issn | 2072-6643 2072-6643 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7071188 |
| source | MEDLINE; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central; EZB Electronic Journals Library |
| subjects | Adaptation Adolescent Adult Adults Aged Appetite Automation Benzhydryl Compounds - administration & dosage Body composition Body fat Body Fat Distribution Body mass Body Mass Index Body size Body weight Body weight loss Caffeine Carbohydrates Cholesterol Counseling Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diet, Reducing Directive Counseling Double-Blind Method Exercise Fat-free body mass Female Food Glucose Glucose - metabolism Glucose transporter Glucosides - administration & dosage Health risks Humans Hunger Ingestion Inhibition Insulin Laboratories Lipids Lipoproteins, VLDL - metabolism Male Metabolic disorders Middle Aged Obesity Obesity - metabolism Obesity - therapy Overweight - metabolism Overweight - therapy Physical fitness Physiological responses Sedentary behavior Short term Side effects Sodium Sodium-Glucose Transporter 2 Inhibitors - administration & dosage Treatment Outcome Triglycerides Triglycerides - metabolism Weight control Weight loss Weight Reduction Programs Young Adult |
| title | Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T18%3A05%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sodium%20Glucose%20Co-Transporter%202%20Inhibition%20Does%20Not%20Favorably%20Modify%20the%20Physiological%20Responses%20to%20Dietary%20Counselling%20in%20Diabetes-Free,%20Sedentary%20Overweight%20and%20Obese%20Adult%20Humans&rft.jtitle=Nutrients&rft.au=Ryan,%20Shane%20P%20P&rft.date=2020-02-18&rft.volume=12&rft.issue=2&rft.spage=510&rft.pages=510-&rft.issn=2072-6643&rft.eissn=2072-6643&rft_id=info:doi/10.3390/nu12020510&rft_dat=%3Cproquest_pubme%3E2362074086%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2395028570&rft_id=info:pmid/32085394&rfr_iscdi=true |